Opinion|Videos|November 5, 2025
Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.
Advertisement
Episodes in this series
Panelists note that patients with ECOG performance status (PS) 2 are underrepresented in clinical trials, making real-world data especially critical in guiding their care.
They highlight how emerging real-world evidence (RWE) provides insight into outcomes and tolerability for these vulnerable populations, supplementing limited trial evidence.
In addition, they discuss how real-world safety signals—sometimes distinct from clinical trials—must be carefully considered when determining treatment sequencing and monitoring approaches.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
4
US Measles Outbreaks Cost Nearly $83 Million in 2026
5